Medicamen Biotech Limited (MEDICAMEQ) AI Stock Analysis

• Market Cap: ₹4.76B
• Dividend Yield: 0.29%
• Average Volume (3M): 1.67K
• Price to Earnings (P/E): 47.5
• Beta (1Y): 1.45
• Revenue Growth: -9.90%
• EPS Growth: 33.18%
• Country: IN
• Employees: 378
• Sector: Healthcare
• Sector Strength: 52
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): 1.59
• Shares Outstanding: 13,562,815
• 10 Day Avg. Volume: 1,527
• 30 Day Avg. Volume: 1,673
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: ₹396.00
• Price Target Upside: 12.77% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 1

• Rating: 54 Neutral
• Price Target: ₹396.00 ▲(12.77% Upside)

Medicamen Biotech Limited's overall score reflects significant financial challenges and weak technical indicators. The high P/E ratio implies overvaluation, while low dividend yield provides little investor income. Financial stability is supported by a solid balance sheet, but liquidity issues due to negative cash flow are concerning.

Medicamen Biotech Limited Business Overview & Revenue Model

Company Description

Medicamen Biotech Limited (MEDICAMEQ) is a pharmaceutical company engaged in the research, development, manufacturing, and marketing of a broad range of pharmaceutical formulations. The company operates in sectors such as healthcare and life sciences, focusing on providing high-quality, affordable medications in various therapeutic categories, including antibiotics, antifungal, antimalarial, cardiovascular, and pain management. Medicamen Biotech Limited serves both domestic and international markets, contributing to global healthcare needs.

How the Company Makes Money

Medicamen Biotech Limited generates revenue primarily through the sale of its pharmaceutical products. The company manufactures and markets a diverse portfolio of generic and branded formulations, which are distributed to pharmacies, hospitals, and healthcare providers. Revenue streams include domestic sales within India and exports to international markets, leveraging its manufacturing capabilities and regulatory approvals. Additionally, the company may engage in strategic partnerships, collaborations, and licensing agreements with other pharmaceutical firms, which can further enhance its market reach and revenue potential. Key factors contributing to its earnings include its ability to maintain competitive pricing, ensure product quality, and expand its product pipeline to meet evolving healthcare demands.

Medicamen Biotech Limited Financial Statement Overview

Summary

Medicamen Biotech Limited demonstrates a mixed financial profile. The income statement shows strength in margins, but revenue growth is inconsistent. The balance sheet is solid, enhancing financial stability. However, cash flow challenges, particularly negative free cash flow, could impact liquidity and require strategic adjustments.

Income Statement

Medicamen Biotech Limited has shown a mixed performance in its income statement. The gross profit margin has been moderately strong, but net profit margin has seen some volatility. Revenue growth has been inconsistent, with significant fluctuations year over year. Notably, EBIT and EBITDA margins are relatively healthy, indicating efficient cost management despite variability in revenue.

Balance Sheet

The balance sheet of Medicamen Biotech Limited reflects a stable financial structure. The company maintains a reasonable debt-to-equity ratio, suggesting moderate leverage. The return on equity is satisfactory, reflecting effective use of equity capital. The equity ratio is solid, showing a strong equity position relative to total assets, which is favorable for long-term solvency.

Cash Flow

Medicamen Biotech Limited's cash flow statement reveals challenges, primarily with negative free cash flow over the past years, indicating potential liquidity issues. The operating cash flow to net income ratio is concerning, as operating cash flow has been negative, suggesting difficulties in converting net income into cash. This could pose risks to financial flexibility if it persists.

Breakdown	TTM	Dec 2025	Dec 2023	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	1.80B	1.63B	1.41B	1.79B	1.15B	1.13B
Gross Profit	660.32M	389.90M	687.74M	852.01M	479.88M	335.16M
EBITDA	222.14M	201.02M	277.12M	245.66M	258.07M	204.25M
Net Income	78.57M	71.08M	148.44M	109.31M	148.98M	121.29M
Balance Sheet
Total Assets	0.00	2.97B	2.79B	2.95B	2.26B	1.94B
Cash, Cash Equivalents and Short-Term Investments	64.15M	37.59M	207.79M	147.86M	38.25M	16.57M
Total Debt	0.00	332.53M	241.83M	311.12M	257.96M	188.19M
Total Liabilities	-2.16B	841.04M	851.03M	875.67M	792.24M	611.18M
Stockholders Equity	2.16B	2.13B	1.93B	2.07B	1.46B	1.33B
Cash Flow
Free Cash Flow	0.00	-119.32M	-128.94M	-130.31M	-44.99M	-51.94M
Operating Cash Flow	0.00	-98.59M	-62.93M	-67.44M	41.09M	127.72M
Investing Cash Flow	0.00	-23.78M	-58.80M	-55.63M	-84.73M	-178.13M
Financing Cash Flow	0.00	12.16M	291.27M	63.13M	42.98M	58.39M

Medicamen Biotech Limited Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 351.15
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:MEDICAMEQ, the sentiment is Negative. The current price of 351.15 is below the 20-day moving average (MA) of 353.38, below the 50-day MA of 379.43, and below the 200-day MA of 448.87, indicating a bearish trend. The MACD of -9.13 indicates Negative momentum. The RSI at 41.24 is Neutral, neither overbought nor oversold. The STOCH value of 36.52 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:MEDICAMEQ.

Medicamen Biotech Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
VENUSREM	68 Neutral	₹6.17B	11.48		―	9.15%	88.32%
INDSWFTLAB	62 Neutral	₹6.18B	2.97		―	-68.96%	-30.30%
SAKAR	61 Neutral	₹7.30B	36.91		―	21.65%	73.16%
MEDICAMEQ	54 Neutral	₹4.76B	47.55		0.29%	-9.90%	33.18%
ZIMLAB	54 Neutral	₹3.62B	38.50		―	-3.36%	-47.58%
Sector *	51 Neutral	$7.95B	-0.40	-42.50%	2.21%	22.29%	-1.85%
NECLIFE	43 Neutral	₹3.29B	30.02		―	-3.41%	-3028.44%